Plain-English translation of NCT06167174 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lupus Nephritis research guide →Researchers are trying to find biological markers in blood and urine that can predict whether patients with lupus-related kidney disease will respond well to standard treatments. Two common medications used are mycophenolate mofetil and cyclophosphamide, both given with steroid medications. By studying blood samples, kidney tissue, and urine before and after treatment, the researchers hope to discover which patients are most likely to benefit from each treatment option.
Right now, doctors cannot reliably predict ahead of time which lupus kidney patients will respond well to treatment. This study aims to find biological clues in the blood and urine that could help doctors choose the best treatment for each patient from the start, potentially avoiding wasted time on ineffective approaches.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be assigned to receive one of two standard treatment approaches for your kidney lupus: either mycophenolate mofetil or cyclophosphamide, both combined with steroid medications. Before and after treatment, researchers will collect samples of your blood, urine, and possibly kidney tissue to analyze for biological markers. The study involves about 100 patients total and is observational, meaning you receive standard medical care while your samples are studied to help predict treatment response.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China
Sponsor
Chinese SLE Treatment And Research Group
Enrollment target
~100 participants
Started
December 2023
Primary completion
December 2027
Age range
16 Years – 60 Years
Last updated on clinicaltrials.gov in December 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xinping Tian, MD
Peking Union Medical College Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.